Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, talks on the use of measurable residual disease (MRD) as a prognostic and predictive biomarker in chronic lymphocytic leukemia (CLL). Whilst MRD is used to define the depth of remission following treatment exposure, it is currently unknown if guiding treatment based on MRD status provides a benefit to patients. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.